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Disseminated tuberculosis among 
hospitalised HIV patients in South 
Africa: a common condition that 
can be rapidly diagnosed using 
urine-based assays
Andrew D. Kerkhoff1, David A. Barr2,3, Charlotte Schutz  3,4, Rosie Burton4,5,6, Mark P. Nicol7, 
Stephen D. Lawn8,9 & Graeme Meintjes3,4
HIV-associated disseminated TB (tuberculosis) has been under-recognised and poorly characterised. 
Blood culture is the gold-standard diagnostic test, but is expensive, slow, and may under-diagnose TB 
dissemination. In a cohort of hospitalised HIV patients, we aimed to report the prevalence of TB-blood-
culture positivity, performance of rapid diagnostics as diagnostic surrogates, and better characterise 
the clinical phenotype of disseminated TB. HIV-inpatients were systematically investigated using 
sputum, urine and blood testing. Overall, 132/410 (32.2%) patients had confirmed TB; 41/132 (31.1%) 
had a positive TB blood culture, of these 9/41 (22.0%) died within 90-days. In contrast to sputum 
diagnostics, urine Xpert and urine-lipoarabinomannan (LAM) combined identified 88% of TB blood-
culture-positive patients, including 9/9 who died within 90-days. For confirmed-TB patients, half the 
variation in major clinical variables was captured on two principle components (PCs). Urine Xpert, urine 
LAM and TB-blood-culture positive patients clustered similarly on these axes, distinctly from patients 
with localised disease. Total number of positive tests from urine Xpert, urine LAM and MTB-blood-
culture correlated with PCs (p < 0.001 for both). PC1&PC2 independently predicted 90-day mortality 
(ORs 2.6, 95%CI = 1.3–6.4; and 2.4, 95%CI = 1.3–4.5, respectively). Rather than being a non-specific 
diagnosis, disseminated TB is a distinct, life-threatening condition, which can be diagnosed using rapid 
urine-based tests, and warrants specific interventional trials.
Tuberculosis (TB) is a leading infectious cause of death worldwide, with an estimated 1.8 million deaths in 20151; 
it also remains the leading cause of death in people living with HIV, contributing to 1 in 3 HIV-related deaths2, 3. 
HIV-associated TB is disseminated (involving multiple organ systems – typically spleen, liver, multiple lymph 
node groups, and/or kidneys) in 90% of post-mortem cases4. By contrast, HIV-seronegative adults dying with 
TB most commonly have sputum-smear positive disease5, 6 and age-associated comorbidities that put them at 
increased risk for death7. While extra-pulmonary pathology is seen in approximately 20% of HIV-uninfected 
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adult TB patients in clinical studies, it tends to be anatomically compartmentalised, pauci-bacillary, and 
rarely fatal8. We therefore suggest that a clear distinction should be made between this (anatomically limited) 
extra-pulmonary TB disease and the disseminated disease seen in association with advanced HIV infection.
This HIV-associated disseminated TB disease phenotype implies ongoing blood stream distribution, 
which is supported by some clinical studies showing a high prevalence of Mycobacterium tuberculosis (MTB) 
blood culture positivity in HIV-associated TB9, 10. By contrast, MTB positive blood cultures are rarely seen in 
immune-competent patients, including those with extra-pulmonary disease (miliary TB accounts for <2% of TB 
cases in adult immune competent patients11), again emphasising the distinctiveness of HIV-associated dissemi-
nated TB.
Despite a presumably high bacillary burden, HIV- associated disseminated TB remains difficult to diagnose. 
HIV-associated TB often has a non-specific clinical presentation (i.e., without cough) and high proportions of 
sputum smear-negative and radiographically non-specific disease12, 13. Therefore, mycobacterial blood culture 
is considered the gold-standard diagnostic test for disseminated TB14. However, a lack of mycobacterial cul-
ture facilities in geographical areas with high HIV-TB burden, and the long incubation time before results are 
obtained, limits the practical use of MTB blood culture for diagnostic purposes9, 15, 16. Consequently, nearly half 
of the HIV-associated disseminated TB observed in post-mortem studies was undiagnosed prior to death4. Even 
when disseminated TB is diagnosed or treated empirically, there is substantial diagnostic delay and patients with 
such severe disease may not survive; the time from initiation of treatment to death is often only a few days, at 
which time culture conversion and mycobacterial suppression has not yet occurred, despite empiric therapy17, 18.
Because disseminated and/or MTB blood culture positive TB is difficult to diagnose ante-mortem, its clin-
ical associations remain poorly described. Only recently has MTB bacteraemia been recognised as one of the 
most common causes of sepsis/severe sepsis in sub-Saharan Africa9, 10. Only a few studies have assessed relative 
mortality risk associated with a positive MTB blood culture9, 19–21. The relationship between MTB blood culture 
positivity and other markers of disseminated HIV-associated TB – such as lipoarabinomannan (LAM) antigenu-
ria – remains unclear22. To date, no intervention trials have specifically focussed on MTB blood culture positive 
patients, and no international consensus guidelines address this condition.
In summary, HIV-associated disseminated TB is clinically distinct from anatomically limited extra-pulmonary 
TB seen in more immunocompetent adults. Disseminated TB is characterised by (and often used interchangea-
bly with) MTB blood culture positivity. HIV-associated disseminated TB or MTB blood culture positive TB are 
under-recognised, which reflects diagnostic failures in HIV-infected patients. There is therefore a pressing need 
to better recognise and characterise HIV-associated disseminated TB or MTB blood culture positive TB to help 
facilitate interventional trials to reduce mortality.
We aimed to describe disseminated TB in a cohort of HIV-infected patients who underwent systematic inves-
tigation for TB disease within 24-hours of admission to hospital. Our objectives were the following: a) to ascer-
tain the prevalence of MTB blood culture positivity, which could then be used as a gold-standard diagnostic 
for disseminated TB in this cohort; b) to determine clinical predictors of MTB blood culture positivity among 
HIV-associated TB inpatients; c) to assess if MTB blood culture positivity could be rapidly and reliably predicted 
by clinical or microbiological surrogates, including sputum and urine based diagnostics (i.e., calculate compara-
tive diagnostic yield); d) to describe the clinical characteristics of HIV-associated TB inpatients in order to define 
a clinical phenotype for HIV-associated disseminated TB; e) to describe the associations between MTB blood 
culture, urine-based diagnostics, disseminated TB clinical phenotype and 90-day mortality.
Methods
Setting and patients. This prospective observational study is a sub-study of a previously reported parent 
study that investigated rapid urine-based approaches (urine LAM lateral-flow assay and urine Xpert) to diag-
nosing HIV-associated TB in inpatients23. The study was conducted from June 2012 to October 2013 at G.F. 
Jooste Hospital in Cape Town, South Africa, an approximately 200-bed district hospital serving several township 
communities in which there is a high prevalence of HIV and incidence of TB24, 25. All patients provided written 
informed consent in their first language. The study was approved by the human research ethics committees of the 
University of Cape Town and the London School of Hygiene & Tropical Medicine and was carried out in accord-
ance with the Declaration of Helsinki.
Four days a week, consecutive adult patients (≥18 years old) who required medical admission were screened 
by a study nurse coordinator who ascertained all medical admissions in the previous 24-hour period from the 
ward register. Any patient previously testing HIV negative or who had an unknown/undocumented HIV status 
was offered rapid HIV testing and counselling23. Patients with previously or newly confirmed HIV-infection were 
approached for consent and recruited to the study regardless of symptomatology or reason for admission. This 
sub-study excluded those with a known TB diagnosis and patients receiving anti-TB therapy prior to current 
hospital admission.
Procedures and samples. The nurse coordinator recorded all demographic and clinical details for recruited 
patients within 24 hours of admission. Specimen collection and TB investigations has been described previ-
ously23, 26. In brief, sputum, urine and blood specimens were obtained from all patients whenever possible within 
24 hours of admission. Two sputum samples were requested from each patient – a spot specimen followed by 
an induced specimen. Urine samples were collected in single-use disposable bed-pans to avoid contamination 
(Litha Healthcare Group, Johannesburg). Venous blood was collected from all patients. The routine (non-study) 
medical team obtained additional samples (sputum and non-respiratory) during admission for TB investigations 
as clinically indicated.
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Laboratory procedures. All biochemistry and haematology tests (including full blood counts, CD4 cell 
counts, HIV viral loads and C-reactive protein [CRP] concentrations) were done at the Groote Schuur Hospital 
National Health Laboratory Service (NHLS). Microbiology specimens were also processed at the NHLS using 
standardised protocols. Sputum samples were tested using fluorescence microscopy, the Xpert MTB/RIF assay 
(Cepheid inc., Sunnyvale, CA, USA) and cultured in mycobacterial growth indicator tubes (MGIT; Becton 
Dickinson, Sparks, MD, USA). Urine was tested using Xpert on fresh urine samples (2.0 ml) as well as frozen 
samples (30–40 ml) that were thawed and concentrated via centrifugation23, 27. Frozen urine samples were also 
thawed and tested retrospectively using the Determine TB-LAM assay (Alere Inc., Waltham, MA, USA) accord-
ing to manufacturer’s instructions; a grade 2 cut-off defined a positive result28. Venous blood samples were 
cultured using Myco F/Lytic culture (Becton Dickinson, Sparks, MD, USA). Culture isolates were identified as 
M. tuberculosis complex with the MTBDRplus line probe assay (Hain Lifescience, Nehren, Germany). All diag-
nostic tests were carried out by independent operators blinded to clinical information and other test results. TB 
results were made available to the routine clinical team to inform treatment decisions with the exception of urine 
LAM lateral-flow assay results, as this test was not endorsed for use by the South African Department of Health 
or the World Health Organization (WHO) at the time of the study.
Clinical outcomes. Vital status at 90 days after study entry as well as subsequent hospital readmission within 
90 days was determined using patient case notes and ward register data in addition to six electronic databases29. 
Those whose vital status could not be determined using one of the above sources were defined as lost-to-follow-up 
(LTFU).
Data analysis. To assess the prevalence of disseminated TB, MTB blood culture positivity was considered the 
gold-standard test, and the analysis was restricted to:
 1. patients with at least one mycobacterial blood culture result (n = 410), to determine prevalence amongst 
HIV-inpatients; and
 2. patients with a new TB diagnosis during admission (n = 132, defined as detection of MTB from one or 
more clinical specimens from any anatomical site using culture and/or Xpert MTB/RIF), to determine 
prevalence amongst inpatients with HIV-associated TB.
To assess clinical predictors of MTB blood culture positivity, Wilcoxon rank-sum tests or Kruskal-Wallis tests 
were used to compare continuous variables and Chi-squared and Fisher’s exact tests to compare proportions. A 
priori variables and variables in the univariable analysis meeting a cut-off of p ≤ 0.1 were assessed in a multivar-
iable logistic regression model. Anaemia severity was defined according to WHO criteria: none (haemoglobin 
concentration ≥13.0 g/dL for males, ≥12.0 g/dL for females), mild (11.0–12.9 g/dL for males, 11.0–11.9 g/dL for 
females), moderate 8.0–10.9 g/dL for males and females) or severe anaemia (<8.0 g/dL for males and females)30.
‘Diagnostic yield’ indicates the real-world performance of a given assay and is the proportion of all confirmed 
diagnoses that were made by a given test and therefore incorporates the ability to obtain specimens for that test 
in clinical practice as well as its sensitivity in the laboratory. To assess the ‘diagnostic yield’ the total number of 
patients with a positive MTB blood culture result was used as the denominator to calculate the comparative ‘diag-
nostic yield’ of TB diagnoses from different assays (microscopy, Xpert, LAM) on different samples types (sputum 
and urine)26. In addition, overall agreement between these tests (microscopy, Xpert, LAM), in which none is 
considered a gold-standard for disseminated TB, was assessed using pairwise Cohen’s Kappa statistics.
Principle components analysis (PCA) was used as a dimension reduction technique to summarise overall clin-
ical variation amongst inpatients with HIV-associated TB on 10 major clinical variables (haemoglobin, mean cor-
puscular volume (MCV), red cell distribution width (RDW), serum sodium, C-reactive protein (CRP), albumin, 
HIV viral load, total lymphocyte count, CD4 cell count, and symptoms, selected a priori). Clinical phenotype, 
defined by the first two principle components (PC1, PC2) of this analysis, was then related to MTB diagnostic 
tests results. A composite score indexing number of tests positive from MTB blood culture, urine LAM and urine 
Xpert (giving a range of possible values between 0 and 3) was calculated for each patient and assessed for cor-
relation with PC1 and PC2 by Spearman’s rank correlation coefficient. Association of PC1 and PC2 with 90-day 
mortality was assessed using logistic regression. For PCA, input clinical variables were selected a priori, missing 
data was imputed by Gibb’s sampling to avoid bias from data missing non-randomly, and varimax rotation was 
used31. All statistical tests were 2-sided at α = 0.05, and were carried out in RStudio version 0.99.892 or STATA 
version 12.0.
Results
Of 609 HIV-positive adults admitted to the adult medical ward, 585 (96.1%) were enrolled in the study and 
systematically investigated for TB. Patients with a known TB diagnosis on admission and/or currently receiving 
TB treatment were excluded (n = 158). Of the 427 remaining patients, 17 did not have blood samples available 
for mycobacterial culture; thus 410 (96.0%) had MTB blood culture results available and were included. These 
patients were predominantly women (n = 249; 61%) with advanced immunodeficiency (median CD4 count, 150 
cells/uL) and anaemia (median haemoglobin, 9.6 g/dL) (Table 1).
Prevalence of TB and MTB blood culture positivity. TB was newly diagnosed (detection of MTB from 
one or more clinical specimens from any anatomical site using culture and/or Xpert MTB/RIF) in 132/410 (preva-
lence, 32.2% [95%CI, 27.7–37.0]) HIV-infected in-patients. Overall, 41 patients had a positive MTB blood culture, 
which accounted for 10.0% (95%CI, 7.3–13.3) of all HIV-infected inpatients and nearly one-third (n = 41/132; 
31.1%) of all HIV-infected inpatients with newly diagnosed TB (‘TB positive | blood culture positive’). Thus, 91 
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HIV-infected inpatients had new active TB disease and were mycobacterial blood culture negative (‘TB positive 
| blood culture negative’), and 278 had no microbiological evidence of TB disease (‘no TB’) (Table 1). No patients 
had non-tuberculous mycobacteria isolated from blood cultures.
All patients 
(n = 410)
TB-positive 
| positive BC 
(n = 41)
TB-positive | 
negative BC 
(n = 91) No TB (n = 278) P-value* P-value**
Age 36.4 (28.9–42.4) 31.1 (26.3–38.2) 34.7 (28.0–40.8) 37.1 (30.0–44.0) 0.002 0.14
Female 249 (60.7) 26 (63.4) 58 (63.7) 165 (59.4) 0.71 0.97
New HIV diagnosis on admission 77 (18.8) 13 (31.7) 18 (19.8) 46 (16.6) 0.07 0.14
ART status
ART-naïve 170 (41.5) 22 (53.7) 45 (49.5) 103 (37.1) 0.11 0.74
Current ART use 172 (42.0) 13 (31.7) 35 (38.5) 124 (44.6)
ART-interrupted 68 (16.6) 6 (14.6) 11 (12.1) 51 (18.4)
If currently on ART, treatment duration 
(years)a 1.6 (0.5–3.5) 0.7 (0.0–2.5) 1.4 (0.2–4.1) 1.6 (0.5–3.6) 0.25 0.29
CD4 counts (cells/uL)b
Median (IQR) cells/µL 150 (55–312) 42 (29–127) 102 (41–225) 191 (74–388) <0.001 0.003
<50 90 (22.1) 24 (58.5) 26 (28.9) 40 (14.4) <0.001 0.001
50–99 62 (15.2) 3 (7.3) 18 (20.0) 41 (14.8)
100–149 52 (12.8) 7 (17.1) 11 (12.2) 34 (12.3)
150–199 41 (10.1 5 (12.2) 10 (11.1) 26 (9.4)
≥200 163 (40.0) 2 (4.9) 25 (27.8) 136 (49.1)
HIV viral load (log copies/mL)c
Median (IQR) 4.4 (1.6–5.5) 5.3 (4.2–6.1) 4.8 (2.7–5.6) 4.0 (1.6–5.4) <0.001 0.025
Virally suppressed (<400 copies/mL) 121 (30.3) 4 (10.8) 21 (23.9) 96 (35.0) 0.003 0.049
Haemoglobin levels (g/dL)d
Median (IQR) 9.6 (7.7–11.6) 7.7 (6.3–8.6) 8.9 (7.0–11.1) 10.2 (8.2–12.2) <0.001 0.002
No/mild anaemia 138 (34.2) 2 (4.9) 25 (27.5) 111 (40.8) <0.001 0.002
Moderate/severe anaemia 266 (65.8) 39 (95.1) 66 (72.5) 161 (59.2)
White cell count (×109 cells/L) d 7.3 (4.9–10.4) 7.2 (5.0–10.1) 7.2 (4.7–9.4) 7.4 (5.1–11.0) 0.34 0.86
Total lymphocyte count (×109 cells/L)e 1.02 (0.65–1.69) 0.64 (0.42–0.87) 0.94 (0.53–1.32) 1.13 (0.74–1.86) <0.001 0.58
Platelet count (×109 cells/L)f 260 (185–356) 207 (123–303) 261 (192–379) 263 (187–360) 0.031 0.012
Albumin concentration (g/L)k 20 (16–27) 18 (13–21) 20 (17–25) 23 (18–28) 0.011 0.06
Sodium concentration (mEq/L)m 133 (129–136) 130 (127–133) 130 (126–134) 134 (130–136) <0.001 0.08
Estimated GFR (mL/min/1.73 m2)b 125 (18–227) 126 (80–167) 129 (95–166) 122 (86–157) 0.54 0.96
C-reactive protein (mg/L)g 72 (17–157) 138 (107–195) 99 (52–174) 53 (12–135) <0.001 0.002
Symptoms
Cough ≥2 weeksb 31 (7.6) 7 (17.1) 10 (11.1) 14 (5.1) 0.010 0.35
Current coughb 192 (47.1) 26 (63.4) 53 (58.9) 113 (40.8) 0.001 0.62
Haemoptysish 29 (7.4) 19 (7.2) 5 (5.7) 5 (13.2) 0.33 0.15
Current feveri 60 (14.7) 8 (20.0) 15 (16.7) 37 (13.4) 0.46 0.54
Current night sweatsb 164 (40.2) 23 (56.1) 44 (48.9) 97 (35.0) 0.006 0.44
Current reported weight lossj 179 (43.8) 25 (61.0) 45 (50.0) 109 (39.2) 0.013 0.24
Positive WHO symptom screenb 375 (91.7) 41 (100) 86 (95.6) 248 (89.2) 0.014 0.31
TB characteristics
History of previous TBa 191 (46.7) 15 (36.6) 33 (36.7) 143 (51.4) 0.020 0.99
TB clinically suspected# 207 (53.5) 29 (72.5) 64 (75.3) 114 (43.5)  < 0.001 0.74
Table 1. Baseline characteristics stratified according to TB status and M. tuberculosis blood culture result Data 
are median (IQR) or number (%). Percentages are column percentages. Abbreviations: ART = antiretroviral 
therapy, GFR = glomerular filtration rate, HIV = human immunodeficiency virus, IQR = interquartile range, 
TB = tuberculosis. a = 172 results available, b = 408 results available, c = 399 results available, d = 404 results 
available, e = 212 results available, f = 403 results available, g = 396 results available, h = 391 results available, 
i = 407 results available, j = 409 results available, k = 110 results available, m = 334 results available. *P-value 
comparison across three groups (n = 410). **P-value compares those with and without positive mycobacterial 
blood cultures among those with confirmed TB (n = 132). #Hospital clinician suspected TB at time of 
admission. Estimated glomerular filtration rate was calculated with the Modification of Diet in Renal Disease 
(MDRD) Study equation 1⁄4 175 (creatinine) 1.154 (Age) 0.203 (0.742 if female) (1.212 if African).
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Predictors of MTB blood culture positivity. Patients with positive MTB blood cultures had more 
advanced immunosuppression compared to patients with negative MTB blood cultures (median CD4 count = 42 
cells/μL; interquartile range [IQR] = 29–127 cells/μL versus median 102 cells/ μL, IQR = 41–225 cells/μL); how-
ever, 14/41 (34.2%) had a CD4 count greater than 100 cells/μL (Table 1). Among MTB blood culture positive 
patients, 13/41 (31.7%) were currently receiving ART, 8/41 (19.5%) had been receiving ART for ≥6 months and 
4/41 (9.8%) were virally suppressed. Notably, 95% of MTB blood culture positive patients had either moderate or 
severe anaemia (median haemoglobin, 7.7 g/dL). They also had higher C-reactive protein (CRP) concentrations 
(median, 138 mg/L) and all had a positive WHO-symptom screen (Tables 1 and 2). In multivariable analysis, 
younger age, lower CD4 cell counts, lower haemoglobin concentrations and higher CRP concentrations were 
independently associated with positive MTB blood culture (Table 2). When multivariable analysis was restricted 
to those with confirmed TB (n = 132), only lower haemoglobin concentrations and lower platelet counts were 
associated with positive MTB blood culture (data not shown).
Outcomes in patients with positive MTB blood culture. Patients with positive MTB blood culture had 
poor outcomes compared to those with negative blood cultures (Table 3). Nearly 60% of those with positive MTB 
blood culture required hospital readmission within 90 days and approximately 44% received at least one blood 
transfusion within 3-months. In total 18/132 (13.6%) TB patients died within 90 days and 9/18 (50.0%) had a pos-
itive mycobacterial blood culture. Thus, 9/41 (22.0%) with positive MTB blood cultures died within 90 days and 
these patients had 2.2-times (95%CI, 1.0–5.2) increased risk of death within 90 days compared to HIV-associated 
TB patients with negative mycobacterial blood cultures. The median time to death in patients with a positive MTB 
blood culture was 20 days (range 6–88 days) from admission.
Diagnostic yield of rapid TB diagnostic tests for detecting TB in those with positive MTB blood 
culture. The median time to mycobacterial blood culture positivity was 26 days (IQR, 23–31 days). Because of 
the delayed time to culture positivity, 5 of the 9 deaths occurred before the culture results were available - demon-
strating the need for rapid TB diagnostics in those with a positive MTB blood culture.
We calculated the comparative diagnostic yield of rapid microbiological assays for detecting TB in patients 
with positive MTB blood culture (Table 4). Rapid sputum-based diagnostics had limited utility for identifying 
patients with positive MTB blood culture, mainly due to the inability of very sick patients to provide sputa. Only 
10/41 (24.4%) patients with positive MTB blood culture were able to produce a sputum sample within 24 hours 
of admission despite use of sputum induction. Thus, sputum smear microscopy and/or Xpert were only able to 
identify TB in 8/41 (19.5% (95%CI, 8.8–34.9)), including only 3 of 9 patients who died within 90 days (Table 4 
and Fig. 1a).
Rapid urine diagnostics performed favourably in patients with positive MTB blood cultures (Table 4 and 
Fig. 1b). The urine LAM lateral-flow assay identified 27/41 (65.9%, 95%CI = 49.4–79.9) of MTB blood culture 
positive patients, while Xpert testing of non-concentrated and concentrated urine samples identified MTB in 
22/41 (53.7% 95%CI, 37.4–69.3) and 32/41 (78.0% 95%CI, 62.4–89.4), respectively. Urine LAM diagnosed TB 
in all 9 patients (100%) with positive MTB blood culture who subsequently died within 90 days of study entry, 
while Xpert testing on non-concentrated and concentrated urine samples identified MTB in 4/9 (44.4%) and 7/9 
(77.8%) of such patients, respectively. A testing strategy combining urine Xpert (on concentrated sample) and the 
urine LAM lateral-flow assay would rapidly detect TB in 87.8% (95%CI, 73.8–95.9) of patients with positive MTB 
blood cultures (Table 4 and Fig. 1b).
Agreement between TB diagnostic assays. Having established urine LAM lateral-flow assay and urine 
Xpert as rapid surrogates for MTB blood culture in the 41 patients with positive MTB blood cultures, we next 
explored how these tests related to each other in the wider cohort of HIV positive inpatients with confirmed TB 
(n = 132).
Urine LAM had moderate agreement with mycobacterial blood cultures (Kappa = 0.52). Urine Xpert run 
on concentrated urine samples had similar agreement with mycobacterial blood cultures (Kappa = 0.48). 
Notably, agreement between concentrated urine Xpert and the urine LAM lateral-flow assay was also moderate 
(Kappa = 0.56). By comparison, agreement of mycobacterial blood culture with sputum smear microscopy and 
Xpert was limited (Kappa = −0.02 and 0.26, respectively).
We therefore hypothesised that urine Xpert and urine LAM, in addition to being surrogates of MTB blood 
culture, were also independent markers of disseminated TB (as opposed to compartmentalized or isolated renal 
TB). To investigate this we assessed how these test results related to clinical phenotypes within the cohort of 
patients with HIV-associated TB.
HIV-associated TB clinical phenotypes. Principal components analysis (PCA) was used to map the dif-
ferent TB diagnostic results on to the main dimensions of clinical variation among 129 patients with confirmed 
TB and complete MTB blood culture, urine LAM lateral flow assay and urine Xpert results. The PCA was con-
structed with 10 a priori defined major clinical variables (Fig. 2A). The first principal component (PC1) summa-
rised 26% of variation; in particular PC1 captured variation in markers of systemic inflammation, including CRP, 
haemoglobin and albumin levels. The second principal component (PC2) summarised a further 18% of clinical 
variation, and represented variation in markers of HIV disease and immune-status (HIV viral load, total lympho-
cyte and CD4 count). PC1 and PC2 were therefore treated as new, composite, independent variables representing 
“inflammation” and “immunosuppression” respectively. Consistent with logistic regression analysis, MTB blood 
culture positivity was strongly related to both the inflammation PC and immunosuppression PC, as was urine 
LAM lateral-flow assay positivity, while urine Xpert positive patients had a more variable phenotype (Fig. 2B).
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Patients with pulmonary TB or anatomically limited forms of extra-pulmonary TB with negative mycobac-
terial blood culture or urine TB assays had similar PC1 and PC2 values (Fig. 2B; pleural TB [positive pleural 
fluid culture] or TB meningitis [positive cerebrospinal fluid culture] versus pulmonary TB, p = 0.67 and p = 0.53, 
respectively by Wilcoxon rank sum test). By contrast, urine Xpert, urine LAM lateral flow assay and MTB blood 
culture, were cumulative in their association with “immunosuppression” and “inflammation”; the total number 
of tests positive from urine Xpert, urine LAM and MTB blood culture (range 0–3) correlated with both “inflam-
mation” (PC1) and “immunosuppression” (PC2) (p < 0.0001 for both; Fig. 2C).
Finally, the ‘inflammation’ and ‘immunosuppression’ composite variables derived from the PCA were inde-
pendently associated with 90-day mortality (Fig. 2D). The total number of tests positive from urine Xpert, urine 
LAM and MTB blood culture was also strongly associated with higher proportional 90-day mortality, reaching 
26.0% in those with a positive MTB blood culture, urine Xpert and urine LAM result (Fig. 3).
Unadjusted RR (95%CI) p-value Adjusted RR (95% CI) p-value
Age, for each year increase 0.95 (0.91–0.98) 0.004 0.95 (0.90–1.00) 0.040
Female 1.13 (0.58–2.22) 0.71
New HIV status 2.21 (1.09–4.50) 0.036 0.91 (0.36–2.27) 0.83
ART status
Current use 1.0 0.24
Naïve 1.81 (0.88–3.74)
Defaulted 1.18 (0.43–3.25)
Previous history of TB treatment
No 1.0 0.17
Yes 0.63 (0.09–0.20)
Current cough
No 1.0 0.027 1.0 0.43
Yes 2.10 (1.08–4.09) 1.41 (0.59–3.36)
Current weight loss
No 1.0 0.012 1.0 0.14
Yes 2.17 (1.12–4.20) 4.20 (0.70–25.39)
Current fever
No 1.0 0.38
Yes 1.47 (0.64–3.36)
Current night sweats
No 1.0 0.030 1.0 0.25
Yes 2.05 (1.07–3.93) 0.33 (0.05–2.01)
CD4 (cells/μL), for every 50 unit decrease 1.61 (1.29–2.01) <0.001 1.32 (1.05–1.66) 0.004
Viral load (copies/mL), for each log unit increase 1.50 (1.18–1.90) 0.003 1.20 (0.89–1.63) 0.23
Haemoglobin (g/dL), for each unit decrease 1.40 (1.22–1.60) <0.001 1.30 (1.09–1.56) 0.003
Platelet (×109 cells/L), for each 10 unit decrease) 1.03 (1.01–1.06) <0.001 1.03 (0.99–1.06) 0.10
Sodium (mmol/L), for each 1 unit decrease 1.06 (0.99–1.14) 0.11
CRP (mg/L), for each 10 unit increase 1.06 (1.03–1.10) <0.001 1.06 (1.01–1.10) 0.013
eGFR (mL/min/1.73 m2), for each unit decrease 0.99 (0.94–1.04) 0.60
Table 2. Multinomial logistic regression of risk factors for M. tuberculosis blood culture positivity*. *Among 
410 patients with mycobacterial blood culture results available.
All patients 
(n = 410)
TB-positive | positive 
BC (n = 41)
TB-positive | negative 
BC (n = 91)
No TB 
(n = 278) P-value
Required hospital readmission 123 (30.0) 24 (58.5) 21 (23.1) 78 (28.1) <0.001
Required blood transfusion 52 (12.7) 18 (43.9) 7 (7.7) 27 (9.7) <0.001
Died 48 (11.7) 9 (22.0) 9 (9.9) 30 (10.8) 0.096
Lost to follow-up 29 (7.1) 1 (2.4) 12 (13.2) 16 (5.8) 0.036
Died or Lost to follow-up 77 (18.8) 10 (24.4) 21 (23.1) 46 (16.6) 0.24
Table 3. Clinical outcomes at 90 days stratified according to TB status and M. tuberculosis blood culture result 
Number (%) are shown. P-value comparison across three groups (n = 410).
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Assay
Diagnostic yield for newly diagnosed TB Diagnostic yield for TB-related deaths
Blood culture positive (n = 41) Blood culture negative (n = 91) Blood culture positive (n = 41) Blood culture negative (n = 91)
Number 
with new TB
Diagnostic yield for 
new TB % (95%CI)
Number 
with new TB
Diagnostic yield for 
new TB % (95%CI)
Number 
of patient 
dying within 
90 days
Diagnostic yield 
in those dying 
within 90 days % 
(95% CI)
Number of 
patients dying 
within 90 
days
Diagnostic yield in 
those dying within 
90 days % (95% CI)
Overall 41 100 91 100 9 100 9 100
Sputum
AFB smear 8 19.5 (8.8–34.9) 17 18.7 (11.3–28.2) 3 33.3 (7.5–70.1) 1 11.1 (0.2–48.2)
Xpert × 1 8 19.5 (8.8–34.9) 25 27.5 (18.6–37.8) 3 33.3 (7.5–70.1) 2 22.2 (2.8–60.0)
Xpert × 2 8 19.5 (8.8–34.9) 27 29.7 (20.5–40.2) 3 33.3 (7.5–70.1) 2 22.2 (2.8–60.0)
Either AFB smear or Xpert × 2 8 19.5 (8.8–34.9) 25 27.5 (18.6–37.8) 3 33.3 (7.5–70.1) 2 22.2 (2.8–60.0)
Urine
LAM Grade 2 27 65.9 (49.4–79.9) 27 29.7 (20.5–40.2) 9 100 (66.4–100) 4 44.4 (13.7–78.8)
LAM Grade 1 32 78.0 (62.4–89.4) 30 33.0 (23.5–43.6) 9 100 (66.4–100) 6 66.7 (29.9–92.5)
Xpert non-concentrated 22 53.7 (37.4–69.3) 34 37.4 (27.4–48.1) 4 44.4 (13.7–78.8) 4 44.4 (13.7–78.8)
Xpert concentrated 32 78.0 (62.4–89.4) 45 49.5 (38.8–60.1) 7 77.8 (40.0–97.2) 8 88.9 (51.8–99.7)
Any urine Xpert 32 78.0 (62.4–89.4) 52 57.1 (46.3–67.5) 7 77.8 (40.0–97.2) 8 88.9 (51.8–99.7)
LAM Grade 2 and non-concentrated Xpert 32 78.0 (62.4–89.4) 43 47.3 (36.7–58.0) 9 100 (66.4–100) 6 66.7 (29.9–92.5)
LAM Grade 2 and concentrated Xpert 36 87.8 (73.8–95.9) 41 45.1 (34.6–55.8) 9 100 (66.4–100) 8 88.9 (51.8–99.7)
LAM grade 2 and any urine Xpert 36 87.8 (73.8–95.9) 55 60.4 (49.6–70.5) 9 100 (66.4–100) 8 88.9 (51.8–99.7)
Table 4. Overview of diagnostic yield of rapid microbiological assays for tuberculosis stratified by 
mycobacterial blood culture result and vital status at 90 days (among n = 132 patients with newly 
diagnosed tuberculosis with mycobacterial blood culture results). Abbreviations: AFB = acid fast bacilli, 
LAM = Lipoarabinomannan. Diagnostic yield is defined as the number of positive test results for given assay 
(numerator; by row) within the total set of patients (denominator; by column).
Figure 1. Venn diagram showing the proportions of Mycobacterium tuberculosis blood culture positive 
patients (n = 41) who had a TB diagnosis made by rapid microbiological tests. (A) Sputum-based 
diagnostics and (B). Urine-based diagnostics. Percentages represent the proportion of patients with positive 
mycobacterial blood culture diagnosed by a respective test and ‘n’ is the actual number of patients with positive 
mycobacterial blood culture diagnosed by a respective test. Any proportion (n) within the red portion was 
not diagnosed by any test, i.e. was exclusively detecting using mycobacterial blood culture. AFB = acid fast 
bacilli, LAM = Lipoarabinomannan. *Both sputum Xpert and sputum microscopy had identical diagnostic 
yield. Sputum microscopy and sputum Xpert had identical diagnostic yield for Mycobacterium tuberculosis 
bacteraemia and both tests diagnosed n = 3/9 Mycobacterium tuberculosis blood culture positive patients who 
died within 90 days.
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Discussion
In this study, MTB blood cultures were positive in 10% of unselected HIV-infected South African adults requiring 
acute medical admission, and nearly one-third of those with newly diagnosed active TB disease. Patients with 
positive mycobacterial blood cultures had high rates of hospital re-admission and MTB bacteraemia was present 
in 22% of all deaths within 90 days of admission. This study adds to prior clinical studies from the last two dec-
ades demonstrating that disseminated TB – defined as culture positive MTB blood culture – is common amongst 
hospitalised HIV-infected patients in sub-Saharan Africa9, 10, 32.
The ability of the Determine TB-LAM lateral-flow assay, a 30-minute point-of-care test that costs less than 
$3 USD per result, to identify TB in the majority of patients with positive MTB blood cultures and identify 
all such patients who died within 90-days was notable. This study builds upon previous studies that have also 
demonstrated an association between urine LAM detection and MTB blood culture positivity33, 34. Our study also 
accords with the results of a recent randomized trial that demonstrated a mortality reduction associated with its 
use35 and strongly supports the recommendation by WHO that urine LAM should be used to aid the detection 
of HIV-associated TB among hospitalized patients with advanced immunodeficiency to allow for more rapid TB 
detection and initiation of potentially life-saving treatment36.
Figure 2. Principle components analysis (PCA) showing main dimensions of variation in laboratory and 
clinical variables for patients diagnosed with TB. The PCA was constructed with 10 major laboratory and 
clinical variables [haemoglobin, mean corpuscular volume (MCV), red cell distribution width (RDW), serum 
sodium, C-reactive protein (CRP), albumin, HIV viral load, total lymphocyte count, CD4 + cell count, and a 
symptom score based on number of ‘TB symptoms’ present (cough, haemoptysis, night sweats, fever, weight 
loss)]. Correlation of each of these variables with the first two principle components (shown as coordinates 
on panel A) demonstrated that the first principle component (PC1, red arrow) of clinical variation was 
dominated by markers of systemic inflammation (e.g. CRP, albumin, haemoglobin) while the second principle 
component (PC2, blue arrow) captured variation in HIV disease and immune status. These PCs were rotated 
using the varimax method and are therefore orthogonal (independent), and explained 26% and 18% of 
variation in the 10 clinical variable respectively. Although not used to construct these PCs, site of TB disease 
groupings clustered distinctively on these dimensions (panel B, each point is PC1 and PC2 coordinates of an 
individual patient, n = 129). PC1 and PC2 varied significantly overall by TB site (Kruskal-Wallis p = 0.003 
and p < 0.001 respectively). Total number of positive tests out of the three assays {urine LAM, urine Xpert, 
M. tuberculosis blood culture} was associated with greater inflammation and immunosuppression (panel 
C). Compartmentalised extra-pulmonary TB in absence of dissemination (i.e. pleural TB or TB meningitis 
with negative urine LAM, urine Xpert and MTB blood culture) had significantly lower PC1 and PC2 values 
compared to disseminated TB. TB 90-day mortality was also strongly associated with “inflammation” and 
“immunosuppression” (panel D); a logistic regression model containing both PC1 and PC2 as independent 
variables showed adjusted odds ratios for mortality of 2.6 (95%CI 1.3–6.4, p = 0.017) and 2.4 (95%CI 1.3–4.5, 
p = 0.005) per one unit (one standard deviation) increase in PC1 and PC2 respectively. uXp = urine Xpert; 
uLAM = urine LAM; BC = MTB blood culture. Suffix “−” = test negative; suffix “ +” = test positive.
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Furthermore, in this study, the addition of urine Xpert to urine LAM testing increased diagnostic yield for 
early identification of patients with positive MTB blood cultures, such that 88% of these patients could be identi-
fied using same-day diagnostic tests. In the near future, urine Xpert may have even greater sensitivity for dissem-
inated TB through the more sensitive Xpert Ultra cartridge and may be more widely available at the point-of-care 
to rapidly inform treatment decisions via the Xpert Omni platform37.
HIV-associated disseminated TB is closely associated with, and possibly synonymous to, MTB blood cul-
ture positivity14 and MTB blood culture positivity remains the gold standard for diagnosis disseminated TB14, 21. 
Post-mortem studies have demonstrated that among the nearly 2 in 5 HIV patients that died who had evidence of 
TB, approximately 90% had disseminated, multi-organ disease and this was almost universally the primary cause 
of death4. This is substantially higher than the proportion of MTB blood culture positive cases among patients 
with HIV-associated TB who died in the present study (9/18 [50%] patients with confirmed TB who died within 
90 days were blood culture positive at study entry). A blood culture only gives a snap-shot of bacteraemia at one 
time point, and bacteraemia in the absence of endo-vascular infection may be intermittent38; even when collected 
at the same time, multiple MTB blood cultures may increase yield39, 40. Consequently, a single blood culture, while 
highly specific, may have imperfect sensitivity for disseminated TB, underestimating the presence and extent of 
bacillary burden.
We found that urine LAM lateral-flow assay, urine Xpert and M. tuberculosis blood culture were cumula-
tive measures of TB disease severity, correlating with systemic inflammation, immune-suppression, and death. 
We therefore speculate that these tests can report a measure of overall mycobacterial dissemination burden in 
patients with HIV-associated TB. MTB bacillary burden has been suspected to be a major driver defining the 
clinical spectrum and outcomes of TB disease, but has, to date, been difficult to measure41, 42. Blood and urine 
samples are accessible in all patients irrespective of clinically detectable extra-pulmonary pathology and can thus 
give an unbiased assessment of disease extent. A simple score based on these tests has potential utility as a quan-
titative marker of MTB bacillary burden for clinical scientists studying HIV-associated TB disease, if validated 
in future work.
Strengths of this study include enrolment of unselected, consecutively recruited HIV-infected adults requir-
ing acute medical admission for any reason, which should make results generalizable to other hospitals in 
Southern and Eastern Africa where the burden of HIV-associated TB is high. Additionally, very thorough, sys-
tematic testing of patients for TB provided a reliable denominator against which the proportion of patients with 
HIV-associated TB with MTB blood culture positivity could be calculated23. Furthermore, mycobacterial blood 
culture results were available for >96% of patients. Our study did however, have limitations. Vital signs and blood 
lactate levels were not systematically recorded and thus we were unable to determine the proportion of patients 
with sepsis syndrome and septic shock due to MTB bacteraemia. Additionally, routine blood cultures were not 
systematically undertaken and thus we do not know what proportion MTB blood stream infection comprised of 
all blood stream infections in this cohort. Finally, TB treatment data was unavailable and we were therefore una-
ble to investigate which patients with positive MTB blood cultures died despite early empirical therapy.
In conclusion, MTB blood culture positivity was identified in one out of every 10 HIV-infected patients 
requiring acute medical admission and was associated with half of HIV-associated TB deaths occurring within 90 
days. Testing of urine samples obtained within 24 hours of admission using Xpert and the urine LAM lateral-flow 
assay identified TB in a large majority of those with positive blood cultures including all such patients who died 
within 90 days. MTB blood culture, urine Xpert and urine LAM results were strongly associated with major axes 
of clinical variation and mortality risk, and we postulate that these three tests in combination are a potential unbi-
ased quantitative marker of MTB bacillary load in patients with HIV-associated disseminated TB. This study adds 
support to the roll out of urine-based point-of-care tests, especially the urine LAM lateral-flow assay, to rapidly 
identify those patients with disseminated disease as a mortality reduction strategy.
Figure 3. Plot of 90-day mortality outcome by number of TB tests positive (urine LAM, urine Xpert, and M. 
tuberculosis blood culture). *Note: area corresponds to absolute count of patients in category; proportion who 
died corresponds to height of red area.
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